Nov. 21 at 5:02 PM
$NVRI As a long-term trader I see Mainz Biomed as a pure asymmetry play: you’ve got CRC prevalence at 154,270 new cases per year in the US alone, only ~67.4% of adults properly screened and just ~37.1% in the 45–49 bracket, then you overlay a test with ~97% CRC sensitivity, ~82% advanced adenomas, 100% HGD and near-97% specificity, all inside a multi-billion dollar screening TAM, I’m happy to let that kind of math work in my favor over years instead of chasing random bounces 🔁
